MRSA drugs: Key market research findings
- Increasing prevalence of infections
- Increased funding for antibiotic research
- Key vendors include Allergan, Merck, Pfizer, and Theravance Biopharma
Technavio has released a new report on the global MRSA drugs market, which is predicted to surpass $3 billion during the forecast period. The global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is anticipated to grow at a slow pace during the forecast period as there is decreased antibiotic research despite the rising incidence of infectious diseases across the globe. Vancomycin is the most widely-used drug for treating the infection in the market. Several pharmaceutical companies are focusing to introduce novel products that will combat resistant strains of infectious pathogens. In 2015, the Americas dominated the market and accounted for around 71% of the total market share. Factors such as the availability of better healthcare infrastructure, coupled with the presence of reimbursement policies and co-pay assistance programs, enables individuals to opt for medical treatments, resulting in huge growth of the MRSA drugs market in the region.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“An increase in the number of infections has created certain unmet needs in the market. This has led to government and non-governmental institutes taking initiatives to develop antibiotics by providing necessary funding to research institutes and companies. For instance, the Obama budget in 2015 granted more than $1 billion to develop antibacterial drugs and fight antibacterial drug resistance and its surveillance. Such financial aids encourage research institutes and companies to make huge investments in antibiotic research, resulting in significant growth of the market,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
Tetracyclines prevent bacterial protein synthesis by reversibly binding to the bacterial 30S ribosomes. They act against Gram-positive and Gram-negative bacteria; however, most of the drugs develop resistance, thereby indicate limited activity. A few commonly prescribed drugs that treat the infection include tetracycline, doxycycline, and minocycline.
The leading vendors in the global MRSA drugs market include Allergan, Merck, Pfizer, and Theravance Biopharma. At present, the market is growing at a slow pace because of the increased use of generics. The unavailability of effective treatment options and increased development of drug resistance is leading to unmet needs in the market. This has led pushed several vendors to engage actively in R&D activities. Also, the market is expected to witness the entry of several new players during the forecast period. The vendors are focusing on both manufacture as well as market their products with high safety and efficacy profile, to gain a competitive edge in the market.
A more detailed analysis is available in the Technavio report, Global MRSA Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
